What am I missing here?This stock could be trading a lot higher soon. What give here. What is the downside?I hope the products are going to get approved soon.........Enjoybody {
...
#12: KERX Stock News : Keryx Biopharmaceuticals Announces Positive Data from a Randomized, Multi-Center, Placebo-Controlled, Phase 2 Combination Study of KRX-0401 (Perifosine) in the Treatment of Advanced Metastatic Colon Cancer
KRX-0401 + Capecitabine More Than Doubles Time to Progression
and Overall Response Rate as well as Extends Overall Survival vs.
Capecitabine + Placebo in Patients with 2nd or 3rd Line...
#11: KERX Stock News : Keryx Biopharmaceuticals Announces Poster Presentations Highlighting Clinical Activity of KRX-0401 (Perifosine) at the Upcoming Annual Meeting of the American Society of Clinical Oncology
Results Will be Reported from Phase 2 Studies Evaluating KRX-0401
in Advanced Renal Cell Carcinoma, Colorectal Cancer and
Gastrointestinal Stromal Tumors (GIST)
NEW YORK, May 18...
Plan to Include Refocusing of Operations and Workforce Reduction
NEW YORK, April 7, 2008 /PRNewswire-FirstCall/ -- Keryx Biopharmaceuticals
(Nasdaq: KERX) today...
NEW YORK, Jan. 3 /PRNewswire-FirstCall/ -- Keryx Biopharmaceuticals, Inc.
(Nasdaq: KERX) today announced that Michael S. Weiss, the Company's Chairman
and Chief...
#8: Keryx Biopharmaceuticals, Inc. Announces Phase 1 and Phase 2 Data on KRX-0401 (Perifosine) in Patients with Relapsed/Refractory Multiple Myeloma at 49th Annual Meeting of American Society of Hematology
Dr. Paul Richardson presents Phase 1 results demonstrating clinical activity of perifosine in combination with bortezomib in patients previously treated with bortezomib, and provides an...
'Room Temp' Technology Builds on Consumer Appeal and Tactical Importance of Needle-less Vaccinations
IRVING, Texas, Dec. 10 /PRNewswire-FirstCall/ -- An experimental drug delivery...
#6: Keryx Biopharmaceuticals, Inc. Announces Poster Presentations Highlighting Observed Clinical Activity of KRX-0401 (Perifosine) to be Presented at the Upcoming American Society of Hematology Meeting in Atlanta, Georgia
Data on Perifosine in the Treatment of Patients with Relapsed/Refractory Multiple Myeloma to be presented on Saturday, December 8th at 5:30pm
NEW YORK, Dec. 7 /PRNewswire-FirstCall/ --...
No Safety Concerns Raised
Sulodexide Phase 3 study to continue without modification
NEW YORK, Dec. 5 /PRNewswire-FirstCall/ -- Keryx Biopharmaceuticals (Nasdaq: KERX) today announced...
#4: Re: Phase 1 & 2 Data of Perifosine (KRX-0401) in Patients with Advanced Renal Cell Carcinoma Presented Today at the 25th Annual Chemotherapy Foundation Symposium
#3: Phase 1 & 2 Data of Perifosine (KRX-0401) in Patients with Advanced Renal Cell Carcinoma Presented Today at the 25th Annual Chemotherapy Foundation Symposium
Oral Presentation by Dr. Robert Figlin Highlights Phase 2 Data Showing 31% Partial Response Rate and a 62% Overall Clinical Benefit Rate to Perifosine Used as a Single Agent and Phase 1...
#2: Keryx Biopharmaceuticals, Inc. Enters into Licensing Agreement with Japan Tobacco and Torii Pharmaceutical for Development and Commercialization of Hyperphosphatemia Drug in Japan
Deal Includes up to $100MM in License Fees and Potential Milestone Payments
NEW YORK, Sept. 26 /PRNewswire-FirstCall/ -- Keryx Biopharmaceuticals, Inc. (Nasdaq: KERX), announced today...
Presentation Scheduled for Wednesday, May 30th at 11:20am PT
Keryx Biopharmaceuticals, Inc. (Nasdaq: KERX Stock Forums) today announced that Michael S. Weiss, the Company's Chairman and Chief...
